New CAR T cell therapy for treating glioblastoma in adults
Development of novel synNotch CART cell therapy in adult patients with recurrent EGFRvIII+ glioblastoma
This study is testing a new treatment for adults with recurring brain cancer called glioblastoma, using specially designed immune cells to better target and kill cancer cells while protecting healthy tissue.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10910095 on NIH RePORTER |
What this research studies
This research focuses on developing a novel CAR T cell therapy specifically designed for adult patients with recurrent glioblastoma, a type of brain cancer. The approach utilizes a synthetic Notch receptor system to enhance the targeting of cancer cells while minimizing damage to healthy tissues. By priming T cells with a specific antigen found in glioblastoma, the therapy aims to effectively eliminate cancer cells that express certain markers, while avoiding harmful effects on other organs. This innovative method addresses challenges such as the variability of antigen expression in tumors and potential off-tumor toxicity.
Who could benefit from this research
Good fit: Ideal candidates for this research are adult patients diagnosed with recurrent EGFRvIII+ glioblastoma.
Not a fit: Patients with glioblastoma who do not express the EGFRvIII mutation or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer treatment option for patients with recurrent glioblastoma.
How similar studies have performed: This approach is innovative and builds on existing CAR T cell therapies, but it specifically targets the unique challenges of glioblastoma, making it a novel endeavor.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Okada, Hideho — University of California, San Francisco
- Study coordinator: Okada, Hideho
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.